Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ROBERT E BARKETT SR.

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1447562970
CMS profile
888069
Location
MANSFIELD, OH

General Payments · PY2018–2024

$2,248.23

  • Reported across 124 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$220.88

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $220.88 13

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $139.91 8
Lilly USA, LLC $37.75 2
NOVARTIS PHARMACEUTICALS CORPORATION $29.90 2
Kowa Pharmaceuticals America, Inc. $13.32 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $238.66 13
PY2019 $138.89 10
PY2020 $348.17 20
PY2021 $331.46 19
PY2022 $424.94 24
PY2023 $545.23 25
PY2024 $220.88 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $13.99 01/16/2024 Food and Beverage Undisputed 01/23/2026 1104429177 CMS
AstraZeneca Pharmaceuticals LP $21.67 01/16/2024 Food and Beverage Undisputed 01/23/2026 1105673787 CMS
AstraZeneca Pharmaceuticals LP $18.30 01/24/2024 Food and Beverage Undisputed 01/23/2026 1105680205 CMS
AstraZeneca Pharmaceuticals LP $16.78 02/28/2024 Food and Beverage Undisputed 01/23/2026 1105459325 CMS
AstraZeneca Pharmaceuticals LP $15.96 03/15/2024 Food and Beverage Undisputed 01/23/2026 1105216267 CMS
AstraZeneca Pharmaceuticals LP $13.56 03/29/2024 Food and Beverage Undisputed 01/23/2026 1105729859 CMS
AstraZeneca Pharmaceuticals LP $19.49 05/13/2024 Food and Beverage Undisputed 01/23/2026 1104569686 CMS
AstraZeneca Pharmaceuticals LP $20.16 06/10/2024 Food and Beverage Undisputed 01/23/2026 1105638622 CMS
Kowa Pharmaceuticals America, Inc. $13.32 12/13/2024 Food and Beverage Undisputed 01/23/2026 1113464079 CMS
Lilly USA, LLC $20.13 02/15/2024 Food and Beverage Undisputed 01/23/2026 1135355552 CMS
Lilly USA, LLC $17.62 04/16/2024 Food and Beverage Undisputed 01/23/2026 1135371034 CMS
Novartis Pharmaceuticals Corporation $14.52 01/12/2024 Food and Beverage Undisputed 01/23/2026 1086673175 CMS
Novartis Pharmaceuticals Corporation $15.38 04/05/2024 Food and Beverage Undisputed 01/23/2026 1086673183 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.